Strive Asset Management LLC Invests $228,000 in Novo Nordisk A/S (NYSE:NVO)

Strive Asset Management LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,649 shares of the company’s stock, valued at approximately $228,000.

Several other large investors have also modified their holdings of the stock. M. Kulyk & Associates LLC raised its position in Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after acquiring an additional 119 shares in the last quarter. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Tradewinds Capital Management LLC raised its position in Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after acquiring an additional 124 shares in the last quarter. Exencial Wealth Advisors LLC increased its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after buying an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC increased its position in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after buying an additional 126 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.7%

NVO opened at $64.35 on Monday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $288.75 billion, a P/E ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15. The business’s fifty day simple moving average is $67.31 and its 200 day simple moving average is $84.19.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an “underperform” rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BMO Capital Markets restated a “market perform” rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.